Year: 2017
Type: review
Abstract: Insulin secretagogues including sulfonylureas, glinides and incretin-related drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists are widely used for treatment of type 2 diabetes. In addition, glucokinase activators and G-protein-coupled receptor 40 (GPR40) agonists also have been developed, although the drugs are not clinically usable. These different drugs exert their effects on insulin secretion by different mechanisms. Recent advances in β-cell signalling studies have not only deepened our understanding of insulin secretion but also revealed novel mechanisms of insulin secretagogues. Clarification of the signalling mechanisms of the insulin secretagogues will contribute to improved drug therapy for diabetes.
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12995
Institution: Kobe University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Elucidation of pathogenesis of diabetes in the novel obese diabetes model ZFDM rat, Elucidation of pancreatic beta-cell function by metabolomics and its clinical application, Establishment of quantification method of glucagon-related peptides and elucidation of pathophysiological role of the peptides
OpenAlex ID: W2751070681
